SHELTON, CT / ACCESS Newswire / May 8, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") ...

SHELTON, CT / ACCESS Newswire / May 8, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today reported that it has received approval from the National Ethics Committee for Health (CNES) of the Ministry of Public Health (MSP), of the Democratic Republic of Congo (DRC).

SPPI

Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo

NanoViricides received regulatory approval in the DRC.
This approval may signal confidence in similar biotech firms.

broad-spectrum-antiviral-drug-nv-387-cleared-for-phase-ii-clinical-trial-application-by-the-national-ethics-committee-of-the-democratic-republic-of-congo

Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo

FAQ

Why Bullish?

How important is it?

Why Short Term?

Related Companies

Related News